Evidence map›Paper›PMID 22275753›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2012

25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages.

Leyuan Xu, Shanwei Shen, Yongjie Ma, Jin Koung Kim, Daniel Rodriguez-Agudo, Douglas M Heuman, Phillip B Hylemon, William M Pandak, Shunlin Ren

Abstract read
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Discovery of a novel regulator, 3β-sulfate-5-cholestenoic acid, of lipid metabolism and inflammation.American journal of physiology. Endocrinology and metabolism · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Larsucosterol: endogenous epigenetic regulator for treating chronic and acute liver diseases.American journal of physiology. Endocrinology and metabolism · 2024
    Review
  8. Cholestenoic acid as endogenous epigenetic regulator decreases hepatocyte lipid accumulation in vitro and in vivo.American journal of physiology. Gastrointestinal and liver physiology · 2024
    Article
  9. Decades Long Involvement of THP-1 Cells as a Model for Macrophage Research: A Comprehensive Review.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Leyuan XuDepartment of Medicine, Virginia Commonwealth University, Richmond, VA 23249, USA.
Shanwei Shen
Yongjie Ma
Jin Koung Kim
Daniel Rodriguez-Agudo
Douglas M Heuman
Phillip B Hylemon
William M Pandak
Shunlin Ren
Virginia Commonwealth University · US

Funding

REGULATION OF CHOLESTEROL METABOLISMR01HL078898 · NHLBI · RICHMOND INSTITUTE FOR VETERANS RESEARCH · PI REN, SHUNLIN · 2006 to 2010
$1.5M
Novel Regulatory Pathway in Prevention of AtherosclerosisI01BX001874 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI REN, SHUNLIN · 2013 to 2016
–
BLRD VA I01 BX000197BLRD VA I01 BX001874NHLBI NIH HHS R01 HL-078898
6 · The paper itself

Abstract

The nuclear receptor peroxisome proliferator-activated receptors (PPARs) are important in regulating lipid metabolism and inflammatory responses in macrophages. Activation of PPARγ represses key inflammatory response gene expressions. Recently, we identified a new cholesterol metabolite, 25-hydroxycholesterol-3-sulfate (25HC3S), as a potent regulatory molecule of lipid metabolism. In this paper, we report the effect of 25HC3S and its precursor 25-hydroxycholesterol (25HC) on PPARγ activity and on inflammatory responses. Addition of 25HC3S to human macrophages markedly increased nuclear PPARγ and cytosol IκB and decreased nuclear NF-κB protein levels. PPARγ response element reporter gene assays showed that 25HC3S significantly increased luciferase activities. PPARγ competitor assay showed that the K(i) for 25HC3S was ∼1 μM, similar to those of other known natural ligands. NF-κB-dependent promoter reporter gene assays showed that 25HC3S suppressed TNFα-induced luciferase activities only when cotransfected with pcDNAI-PPARγ plasmid. In addition, 25HC3S decreased LPS-induced expression and release of IL-1β. In the PPARγ-specific siRNA transfected macrophages or in the presence of PPARγ-specific antagonist, 25HC3S failed to increase IκB and to suppress TNFα and IL-1β expression. In contrast to 25HC3S, its precursor 25HC, a known liver X receptor ligand, decreased nuclear PPARγ and cytosol IκB and increased nuclear NF-κB protein levels. We conclude that 25HC3S acts in macrophages as a PPARγ ligand and suppresses inflammatory responses via the PPARγ/IκB/NF-κB signaling pathway.

Indexed as

Anti-Inflammatory AgentsBlotting, WesternCell NucleusCholesterol EstersCytokinesCytosolEnzyme-Linked Immunosorbent AssayHumansHydroxycholesterolsHypoglycemic AgentsI-kappa B ProteinsLipopolysaccharidesMacrophagesNF-kappa BPPAR gammaProtein Transport25-hydroxycholesterol 3-sulfateAnti-Inflammatory AgentsCholesterol EstersCytokinesHydroxycholesterolsHypoglycemic AgentsI-kappa B ProteinsLipopolysaccharidesNF-kappa BPPAR gammaRNA, MessengerRNA, Small InterferingRosiglitazoneThiazolidinediones

Identifiers

PMID22275753
PMCPMC3330710
OpenAlexW2139500737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.